UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June 23~~July 27, 2026

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-42914	83-2163243
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Tradingsymbol~~Trading symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Voting Common Stock, $0.0001 par value per share		MPLT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5 7.0701 ~~Submission~~Regulation ofFD ~~Matters to a Vote of Security Holders~~Disclosure.

On ~~June~~July 2327, 2026, MapLight Therapeutics, Inc. (the “Company”) ~~held~~will ~~its~~hold ~~2026~~a ~~annual~~conference ~~meeting~~call ofto ~~stockholders~~discuss (the ~~“Annual~~topline ~~Meeting”).~~results Atfrom ~~the Annual Meeting~~ZEPHYR, ~~the~~a ~~stockholders~~Phase ~~considered~~2 ~~two~~trial ~~proposals, each~~ of ~~which~~ML-007C-MA ~~is described~~ in ~~more~~inpatient ~~detail~~adult inparticipants ~~the Company’s definitive proxy statement filed~~ with ~~the~~schizophrenia ~~Securities~~experiencing ~~and~~an ~~Exchange~~acute ~~Commission~~exacerbation onof ~~April 29,~~psychosis ~~2026~~ (the “~~Proxy~~ZEPHYR ~~Statement~~Trial Results”). Of ~~the~~A ~~42,610,079 shares~~copy ~~outstanding as~~ of the ~~record~~presentation ~~date,~~that ~~36,883,750~~will ~~shares,~~accompany orthe ~~approximately~~conference ~~86.56%,~~call ~~were~~is ~~present~~furnished orherewith ~~represented~~as byExhibit ~~proxy at the Annual Meeting~~99.1 ~~Set~~to ~~forth~~this ~~below~~Current ~~are~~Report ~~the~~on ~~results~~Form ~~of the matters submitted for a vote of stockholders at the Annual Meeting~~8-K.

~~Proposal~~In Noaccordance with General Instruction B. 2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1: ~~Election~~hereto shall not be deemed “filed” for purposes of ~~three~~Section 18 ~~nominees~~of tothe ~~serve~~Securities Exchange Act of 1934, as ~~directors~~amended ~~until~~(the “Exchange Act”), or otherwise subject to the ~~2029~~liability ~~annual~~of ~~meeting~~that section, nor shall it be deemed incorporated by reference in any of ~~stockholders~~the ~~and~~Company’s ~~until~~filings ~~their~~under ~~respective~~the ~~successors~~Securities ~~are~~Act ~~elected~~of ~~and~~1933, ~~qualified.~~as ~~The~~amended, ~~votes~~or ~~were~~under ~~cast~~the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as ~~follows:~~expressly set forth by specific reference in such a filing.

Name	Votes For		Votes Withheld
Martin Babler		31,424,194		3,575,737
Troy Cox		34,979,012		20,919
George Pavlov		34,220,342		779,589

Item 8.01 Other Events.

~~Broker~~On July ~~Non-Votes: 1~~27,~~883~~ 2026,~~819~~ the Company issued a press release announcing the ZEPHYR Trial Results. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

~~All~~Item ~~nominees~~9.01 ~~were~~Financial ~~elected.~~Statements and Exhibits.

~~Proposal~~(d) ~~No. 2:~~Exhibits ~~Ratification of the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:~~

	Votes For		Votes Against		Abstained
ExhibitNumber	Exhibit Description
Ratification of selection of RSM US LLP		36,859,217		22,332		2,201
99.1	Company Presentation, dated July 27, 2026.
99.2	Press Release, dated July 27, 2026.
104	Cover Page Interactive Data File (formatted as inline XBRL).

Broker Non-Votes: 0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MapLight Therapeutics, Inc.

Dated: June 24, 2026

/s/ Christopher A. Kroeger

Dated: July 27, 2026

/s/ Christopher A. Kroeger

Christopher A. Kroeger, M.D.

Chief Executive Officer

Filing Compare · MapLight Therapeutics, Inc.